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ABSTRACT
The non-coding 30-untranslated region (UTR) plays
an important role in the regulation of microRNA
(miRNA) functions, since it can bind and inactivate
multiple miRNAs. Here, we show the 30-UTR of CD44
is able to antagonize cytoplasmic miRNAs, and
result in the increased translation of CD44 and
downstream target mRNA, CDC42. A series of cell
function assays in the human breast cancer cell line,
MT-1, have shown that the CD44 30-UTR inhibits pro-
liferation, colony formation and tumor growth.
Furthermore, it modulated endothelial cell activities,
favored angiogenesis, induced tumor cell apoptosis
and increased sensitivity to Docetaxel. These
results are due to the interaction of the CD44
30-UTR with multiple miRNAs. Computational algo-
rithms have predicted three miRNAs, miR-216a,
miR-330 and miR-608, can bind to both the CD44
and CDC42 30-UTRs. This was confirmed with
luciferase assays, western blotting and immunohis-
tochemical staining and correlated with a series of
siRNA assays. Thus, the non-coding CD44 30-UTR
serves as a competitor for miRNA binding and sub-
sequently inactivates miRNA functions, by freeing
the target mRNAs from being repressed.
INTRODUCTION
CD44 is a transmembrane glycoprotein that exists in
several isoforms with different extracellular regions. It is
involved in a wide range of cellular functions including
cell–cell and cell–matrix interactions, lymphocyte activa-
tion and homing, haematopoiesis, tumor metastasis and
cell migration (1–3). The various transcripts of CD44 are
encoded for by one-gene locus on chromosome 11, which
contains 20 exons (4). These transcripts undergo complex
alternative splicing resulting in many functionally distinct
isoforms (3). Thus, the alternative splicing is the basis for
the structural and functional diversity of this protein, and
may be related to tumor metastasis (5). The standard form
of CD44, CD44H, plays a role in cell locomotion in the
presence of glycosaminoglycan chains and is considered to
enhance the tumorigenic properties of some lymphomas
and melanomas (6). As opposed to the standard form of
CD44, which is abundant in many tissues, isoforms
encoded by the variant exons are highly restricted in
their distribution in non-malignant tissues. In some
cancers, CD44 upregulation is associated with a favorable
outcome, such as in epithelial ovarian cancer; its increased
expression is seen as an indicator of increased survival
time (7). This is also the case with Burkitt’s lymphoma,
neuroblastoma and prostate cancer, where the loss of
CD44 expression is accompanied with oncogenic
transformation (8). Our recent study indicated that ex-
pression of CD44 is regulated by microRNA (miRNA)
miR-328 (9).
The miRNAs are 18–24 nucleotides of single-stranded
RNAs, which are transcribed from the genome and are
regulators of mRNAs. The mRNAs that are bound by
miRNAs are targeted for degradation and are transported
to p-bodies leading to the translational repression of
mRNAs (10). There are over 700 miRNAs that have
been sequenced and reported, and it is estimated that
one-third of genes are regulated by miRNAs as one
miRNA can regulate the expression of many genes (11).
By silencing various target mRNAs, miRNAs have key
roles in controlling diverse regulatory pathways including
development, apoptosis, protein secretion and cell prolif-
eration (12–17). Furthermore, the deregulation of
miRNAs has been implicated in a growing number of
diseases, including cancer development (18,19). It has
been reported that miRNAs are aberrantly expressed in
human breast cancer (20). The expression of some
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biopathological features, such as estrogen and progester-
one receptor expression, vascular invasion, lymph node
metastasis, tumor stage and proliferation index (21–23).
Usually miRNAs function by targeting the 30-UTRs of
mRNAs. There are several regulatory sequences found in
the 30-UTR: a polyadenylation signal that marks the site
of cleavage of the transcript  30-nt downstream of the
signal; binding sites for AU-rich element binding
proteins, which can stabilize or destabilize the mRNA
depending on the protein; binding sites for miRNAs
(24,25). The 30-UTR is well known to be involved in the
stability, nuclear transport, cellular localization and trans-
lational efﬁciency of mRNAs (25,26). Furthermore, some
30-UTRs are subjected to alternative splicing (27), which
can be postulated to occur in order for the 30-UTR to
escape miRNA regulation in different biological activities.
Recent studies have demonstrated that the 30-UTRs
are the most important target sites for miRNAs.
We hypothesized that the 30-UTR can also play a role in
feedback regulation of miRNA functions. This study was
designed to investigate whether the exogenous over-
expression of CD44 30-UTR could affect miRNA
functions.
MATERIALS AND METHODS
Construct generation
To study the effect of CD44 30-UTR on cell activities, we
have cloned the 30-UTR by using an existing construct
that was previously made in the lab—Luc-CD44 30-UTR
(9). The CD44 30-UTR fragment was digested with restric-
tion enzymes NheI and ApaI and inserted into NheI- and
ApaI-opened pcDNA3.1 vector. The protein expression
construct of CD44E was also previously used in the lab
(9) and was a kind gift from Dr Warren Knudson (28).
A luciferase reporter vector (pMir-Report; Ambion)
was used to generate the luciferase constructs. The differ-
ent lengths of the CDC42 30-UTR was cloned using PCR.
The PCR products were then digested with SacI and MluI
and the fragment was inserted into a SacI- and MluI-
digested pMir-Report Luciferase plasmid (Ambion),
to obtain the different luciferase constructs. A mutant
construct for each 30-UTR was also generated using a
similar approach with PCR. The control, a non-related
sequence, was ampliﬁed from the coding sequence of the
chicken versican G3 domain and was previously con-
structed in the lab (29). It is expected that there are no
endogenous miRNAs that bind to this fragment as it is in
the coding region.
Four different siRNA constructs complementary to
CD44 30-UTR sequences were generated. The CD44
30-UTR MT-1 cells were seeded at the density of 2 10
5
cells per well in 6-well plates in 2ml culture medium
containing serum. After 24h, cells were washed twice
with serum-free medium, then transfected with the four
different siRNA constructs using Lipofectamine
TM 2000
(Invitrogen). Forty-eight hours after transfection, cells
were harvested by exposure to trypsin and then subjected
to the various assays.
RNA analysis
Expression of the CD44 30-UTR was conﬁrmed by extrac-
tion of RNA (Qiagen RNAeasy
TM) from cells stably
transfected with pcDNA3.1-CD44 30-UTR and the
empty vector control. Primers for the CD44 30-UTR
were used in a PCR reaction were previously used in our
lab (9). RT–PCR for GAPDH was performed as endogen-
ous loading control.
For real-time PCR, total RNA was extracted from cell
cultures using the mirVana
TM miRNA Isolation Kit
(Ambion) according to the manufacturer’s instructions.
RT–PCR were performed as previously described (9).
The primers for CD44 30-UTR were previously used in
our lab (9). The primers used as the real-time PCR
controls were human-U6RNAf and human-U6RNAr.
Cell proliferation assays
Transfected-MT-1 cells were seeded onto 100-mm tissue
culture plates at a density of 1 10
5 cells/plate in DMEM
containing 10% FBS and maintained at 37 C for up to
5 days. The cells were harvested and cell number was
counted with a Coulter counter.
For cell-cycle analysis, cells were seeded at 90%
conﬂuence onto tissue culture plates in DMEM con-
taining 5% FBS and maintained at 37 C for 24h. Cell
were trypsinized and resuspended in HBSS with 2% calf
serum. Cells were then ﬁxed with 80% ice cold ethanol for
30min and resuspended in HBSS containing 0.1mg/ml
propidium iodide (PI), 0.6% of NP-40 and 2mg/ml
RNAseA (Bovine Pancreas Type II, Sigma) for 30min.
The DNA content was measured by ﬂow cytometry
(Beckman Coulter).
Cell survival assays
For survival assays, cells were seeded at the density of
2 10
5 cells/well in 6-well plates in 2-ml culture medium
containing serum. After 24h, cells were washed twice with
PBS, and then incubated in serum-free medium. At differ-
ent time points, cells were harvested and the viable cells
were counted after Trypan Blue staining.
For annexin V apoptosis assays, the cells were grown in
low serum (1%) or serum-free conditions for 5 days. The
cells were separately washed twice with cold PBS and
stained with binding buffer containing ﬂuorescein-labeled
annexin V and with PI (APC Annexin V Apoptosis
Detection Kit I, BD Pharmingen) following manufactur-
er’s instructions. The cells that were positive for apoptosis
(APC annexin V positive, PI negative or APC annexin
V positive, PI positive) were analyzed by ﬂow cytometry.
To test their drug sensitivity, the cells were cultured in
DMEM medium supplemented with 10% FBS, and anti-
biotics. After cells adhered to the plate, 1mM of Docetaxel
(Sanoﬁ-aventis Canada Inc.) was added. Cell numbers
were counted 24h after Docetaxel addition.
Colony and tumor formation assays
Colony formation was assessed by plating 1 10
3 cells in
0.3% low-melting agarose (Seaplaque, FMC) and DMEM
supplemented with 2% FBS. This mixture was placed on
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weeks after plating, colonies were examined and photo-
graphed under a light microscope.
In the tumor formation experiments, CD44 30-UTR and
control MT-1 cells (2 10
6 cells) were injected subcutane-
ously into 5-week-old CD1 strain nude mice (Jackson
Laboratories) and tumor volume was measured
every 5 days. BrdU was injected at a concentration of
50mg/kg 24-h prior to the mice being sacriﬁced for
tumor excision. Tumor volume (V) was measured using
a caliper by measuring the length (L) and width (W),
where V=(L W
2)/2. When the sizes of the tumors
were above the limit described by the animal protocol
approved by the Animal Care Committee at
Sunnybrook Health Sciences Centre, the mice were
sacriﬁced and the tumors were removed. Tumors were
ﬁxed in 10% buffered formalin, processed and
embedded in parafﬁn.
Immunoreaction
Western blot and immunohistochemistry were performed
as previously described (9,29–31).
Tube formation assay
YPEN-1 cells were mixed with the CD44 30-UTR or
control cells and cultured in BD Matrigel
TM (Basement
Membrane Matrix, BD Biosciences). The interaction of
both types of cells and the formation of tube structures
were examined after 24h by light microscopy and
photographed.
Luciferase activity assays
MT-1 cells were cultured on 24-well tissue culture plates at
a density of 3 10
4 cells/well in DMEM containing 10%
FBS. The cultures were maintained at 37 C for 24h,
followed by co-transfection with the luciferase reporter
constructs and miRNAs using Lipofectamine 2000 follow-
ing the methods described by us recently (9,32).
Statistical analysis
The results (mean values±SD) of all experiments were
subjected to statistical analysis by t-test.
RESULTS
Expression of CD44 30-UTR decreases tumor growth
To study the effect of the CD44 30-UTR on miRNA
function, we exogenously overexpressed the CD44
30-UTR in human mammary carcinoma cells (MT-1).
MT-1 is an established estradiol and progesterone
receptor-negative breast cancer cell line, which was origin-
ally obtained from surgical material that was transplanted
in nude mice (33). They are optimal cells for this study
because they have been routinely used as a breast cancer
xenograft model in tumor growth and breast cancer pro-
gression studies (34–36). Initially, the MT-1 cell line was
stably transfected with a pcDNA3.1-CD44 30-UTR ex-
pressing construct (Figure 1a). A control cell line was
established with the stable transfection of an empty
pcDNA3.1 vector. Another MT-1 cell line was also estab-
lished that stably expressed CD44E, coding region of the
epithelium form of CD44. Total RNA from pooled stable
CD44 30-UTR- and empty vector-transfected cells were
subjected to RT–PCR using random primers (Figure 1a)
and oligo-dT primer (Supplementary Figure S1a) for
reverse transcription. The PCR products were analyzed
on agarose gel electrophoresis to conﬁrm expression of
the 30-UTR. Expression of CD44 30-UTR were also
analyzed by real-time PCR in MT-1 cells transfected
with the 30-UTR construct or control vector. The levels
of CD44 30-UTR in the CD44 30-UTR-transfected cells
were 3-fold over that of the control, which displayed the
endogenous level of CD44 30-UTR. This conﬁrmed that
the CD44 30-UTR is being expressed from the CD44
30-UTR plasmid in the stable cell line. The CD44
30-UTR appeared to be stable in the cells, since
we always detected much higher levels of the 30-UTR in
the CD44 30-UTR transfected cells compared with the
control.
A series of cell function assays were performed with the
CD44 30-UTR, CD44E and control cells. In cell prolifer-
ation assays, the CD44 30-UTR cells showed a decreased
proliferation rate compared with the controls (Figure 1b).
In colony formation assays, cells were plated in
low-melting agarose with 2% FBS. These conditions
allowed cells to expand and form 3D colonies after 2
weeks. The control cells and CD44E cells formed bigger
and more colonies per plate than the stable CD44 30-UTR
cells (Figure 1c). These results were correlated with
cell-cycle analysis; the CD44 30-UTR cells had a larger
population of cells in the G1 (resting) phase than the
control cells (Figure 1d). As well, the control cells had
larger populations in the S (synthesis) and G2 (mitotic)
phases, implying that they had an increased amount of
cells actively dividing compared with the CD44 30-UTR
cells.
The tumorigenic potential of CD44 30-UTR-transfected
cells was tested in nude mice. Repeated experiments
showed that expression of CD44 30-UTR greatly
decreased the tumorigenic potential of cancer cells
compared with control mice (Figure 1e). Bromodeo-
xyuridine (BrdU), which is commonly used in the detec-
tion of proliferating cells in living tissues, was injected into
the mice 24h before sacriﬁce and tumor sections were
stained with a BrdU-FITC antibody. A decrease in
BrdU staining was observed in the CD44 30-UTR
tumors explaining their diminished growth rate
compared with the controls (Supplementary Figure S1b).
Overexpression of CD44 30-UTR promotes cell death
The effect of the overexpression of exogenous CD44
30-UTR on cell survival was monitored, when the CD44
30-UTR and control MT-1 cells were maintained in tissue
culture dishes in low serum and serum-free conditions.
The CD44 30-UTR cells had a decreased rate of cell
survival. Surviving cells were harvested and counted for
statistical analysis (Figure 2a). The cells were also sub-
jected to apoptosis assays to conﬁrm these results. The
CD44 30-UTR and control cells were cultured in low
3028 Nucleic Acids Research, 2011,Vol.39, No. 8serum and serum-free conditions for 5 days, stained with
annexin V and PI and analyzed by ﬂow cytometry.
The CD44 30-UTR cells had a larger population of apop-
totic cells (Annexin V positive, PI positive and Annexin
V positive and PI positive) compared with the control cells
in both serum-free (0%) and low-serum (1%) conditions
(Figure 2b). Furthermore, the CD44 30-UTR tumor
sections exhibited more apoptotic cells than the control
tumor sections when subjected to TUNEL staining
(Figure 2c). In addition, cells expressing CD44 were
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Figure 1. The CD44 30-UTR decreases cell proliferation and tumor formation. (a) A fragment of CD44 30-UTR (900bp) was inserted into the
pcDNA3.1 plasmid, downstream of the CMV promoter, NheI and ApaI sites, producing the CD44-UTR construct. Total RNA from CD44 30-UTR
and control cells were subjected to RT–PCR, and analyzed by agarose gel electrophoresis. CD44 30-UTR cells had an increased expression of CD44
30-UTR compared to control cells. There was a 3-fold increase in CD44 30-UTR levels in the CD44 30-UTR cells compared with the control cells as
analyzed by real-time PCR. **P<0.01. (b) The CD44 30-UTR, control and CD44E-transfected cells were plated and cell numbers were counted over
a period of 5 days. The CD44 30-UTR decreased cell proliferation of MT-1 cells. n=5,**P<0.01. (c) Control and CD44E cells formed bigger and a
higher amount of 3D colonies per plate than the CD44 30-UTR cells when plated in low melting agarose with 2% FBS. n=3, *P<0.05. (d) The
CD44 30-UTR cells had a larger population in the G1 phase and smaller populations in the S and G2 phases than the control cells as determined by
cell cycle distribution through FACs analysis (left). Typical FACs proﬁles are shown (right). n=3,*P<0.05. (e) MT-1 cells stably transfected with
the CD44 30-UTR or control plasmid were injected subcutaneously into nude mice and tumor growth was monitored for 15 days. Expression of the
CD44 30-UTR decreased tumor growth compared with the vector control (left). Typical mice and tumor sizes are shown (right). n=10, *P<0.05,
**P<0.01.
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Figure 2. The CD44 30-UTR promotes cell death. (a) CD44 30-UTR and control cells were maintained in tissue culture dishes in low serum and
serum-free conditions. Surviving cells were harvested and counted. The CD44 30-UTR cells had a decreased rate of survival (upper). Cell survival was
also monitored by light microscopy and photographs (lower). n=3, **P<0.01, scale bars=100mm. (b) CD44 30-UTR and control cells were
cultured in low serum and serum-free conditions for 5 days. The cells were stained with Annexin V and PI and analyzed by ﬂow cytometry. The
30-UTR cells had a larger population of apoptotic cells (Annexin V positive, PI positive and Annexin V and PI positive) compared with the control
cells in both 0% and 1% serum conditions. (c) Tumor sections of CD44 30-UTR and the controls were co-immunostained for the expression of CD44
(red) and apoptotic cells (green). The areas of cells expressing high levels of CD44 were associated with apoptotic cells.
3030 Nucleic Acids Research, 2011,Vol.39, No. 8associated with staining for apoptotic cells. When tumor
sections were subjected to H&E staining, nuclear conden-
sation and fragmentation were present in the CD44
30-UTR tumor sections, but not in the control tumor
sections (Supplementary Figure S1c). The CD44 30-UTR
and control cells were also treated with Docetaxel, a
common chemotherapeutic drug. The experiments
indicated that the control cells were resistant to docetaxel
treatment, which allowed them to survive longer
compared with the CD44 30-UTR cells (Supplementary
Figure S1d).
Expression of CD44 30-UTR enhances endothelial cell
activities and angiogenesis
Another series of cell function assays were performed to
determine the endothelial cell activities affected by the ex-
pression of the CD44 30-UTR. YPEN-1 is a rat endothelial
cell line and can form tube-like structure in Matrigel
TM
(31,37). YPEN-1 cells have been previously used by our
lab to examine tube formation. The CD44 30-UTR and
control cells were mixed with YPEN-1 cells and cultured
in Matrigel
TM
to examine tube formation. The CD44
30-UTR cells were able to form larger cell network
complexes and longer tubes with YPEN-1 cells
compared with the control cells (Figure 3a). To further
test the endothelial functions in vivo, we examined blood
vessels in tumor sections by immunostaining for CD34
expression, which is expressed in early hematopoietic
and vascular-associated tissue and is a marker for blood
vessels. There was an increase in blood vessels in the CD44
30-UTR tumor sections compared with the control tumor
sections (Figure 3b). Co-immunostaining for apoptotic
cells and blood vessels were performed to determine
whether or not the increase in blood vessels correlated
with the presence of apoptotic cells. Indeed, the
enhanced amount of blood vessels in CD44 30-UTR
tumor sections (red) did not result in a lower amount of
cell death (green) as apoptotic cells were noticed in areas
of large blood vessels compared with the control sections
(Figure 3c). Thus, the increased number of blood vessels
was unable to rescue the CD44 30-UTR cells from death.
Targeting analysis of CD44 30-UTR
Analysis with computational algorithms showed that
many miRNAs could potentially bind to the CD44
30-UTR. Since each of these miRNAs in turn could
target many mRNAs, we searched for mRNAs that
encode proteins involved in cell proliferation, and
miRNAs that could target these mRNAs with a high po-
tential of translational repression and could bind to the
CD44 30-UTR with low binding energy. One of these is
CDC42, a Rho-GTPase involved in the regulation of sig-
naling pathways to control cell morphology, migration
and cell-cycle progression. CDC42 has been shown to be
able to alter growth factor signaling and inhibit cell cycle
progression in G1 phase (38,39). Bioinformatical analysis
identiﬁed three miRNAs, miR-216a, miR-330 and
miR-608, which were predicted to target CDC42 expres-
sion and could bind to the CD44 30-UTR with low energy
(Figure 4a). We hypothesized that overexpression of
CD44 30-UTR by the CMV promoter would bind and
arrest these three miRNAs and free the endogenous
mRNAs of CD44 and CDC42 for translation (Figure 4b).
To conﬁrm the targeting of miR-216a, miR-330 and
miR-608 to the CDC42 30-UTR, a series of luciferase
assays were performed with each miRNA and CDC42
pMIR-report construct (Luc-CDC42-216,
Luc-CDC42-330 and Luc-CDC42-608) or their mutant
construct (Luc-CDC42-216-mut, Luc-CDC42-330-mut
and Luc-CDC42-608-mut). The mutated sequences are
shown in red in Figure 4a and the structures of the con-
structs are shown in Supplementary Figure S2. All pre-
dicted miRNAs were found to possess the repressive
activities on CDC42 30-UTR linked to a luciferase
reporter construct, which resulted in a decrease in
luciferase activities (Figure 4c and Supplementary
Figure S3a). When the miRNA binding sites were
mutated, there was a restoration in luciferase activities.
This also occurred when the pcDNA3.1–CD44 30-UTR
was transfected along with each CDC42 30-UTR and cor-
responding miRNA, demonstrating that the miRNA is
able to be bound by the CD44 30-UTR (Figure 4d for
MT-1 cells and Supplementary Figure S3b for U343 cells).
To test whether multiple miRNAs could bind to the
CD44 30-UTR, a luciferase assay was performed with a
luciferase vector containing the CD44 30-UTR (Luc-CD44
30-UTR) or a scrambled control sequence (control). With
an increased amount of CD44 30-UTR transfected, there
was an increase in luciferase activities (Figure 4e).
However, the luciferase activities of Luc-CD44 30-UTR
never reached the levels of the control. This suggests
that endogenous miRNAs were targeting the CD44
30-UTR. Due to increased supplies of the CD44 30-UTR,
some endogenous miRNAs were absorbed, which allowed
luciferase translation to occur. Another set of luciferase
experiments were used to examine the function of the
CD44 30-UTR in a competition assay. The Luc-CD44
30-UTR and Luc-Ctrl constructs were co-transfected
with the pcDNA3.1-CD44 30-UTR (vector CD44
30-UTR) construct at different amounts (Figure 4f). The
increased amounts of CD44 30-UTR bound more en-
dogenous miRNAs freeing the translation of the luciferase
protein, resulting in higher levels of luciferase activities.
Upregulation of CD44 and CDC42 by expression of
CD44 30-UTR
We reasoned that the increased expression of CD44
30-UTR should result in an increase in CD44 and
CDC42 protein levels. This occurred because miRNAs
would bind to the exogenously transfected CD44
30-UTR freeing the endogenous mRNAs of CD44 and
CDC42 (Figure 4b). This was conﬁrmed by western blot
using cell lysates from CD44 30-UTR and control cells. We
observed an elevated expression of CD44 and CDC42
proteins in the CD44 30-UTR-transfected cells compared
with the control cells (Figure 5a). To conﬁrm that the
CDC42 upregulation was a consequence of CD44
30-UTR overexpression rather than a result of elevated
CD44 levels, we exogenously expressed a CD44E-
construct in the MT-1 cells. While we detected an
Nucleic Acids Research,2011, Vol.39, No. 8 3031increased expression of CD44, reaching levels equal to
that of CD44 in the CD44 30-UTR-transfected cells, we
did not detect an increased expression of CDC42 (Figure
5b). These results indicated that increased expression of
CDC42 was a consequence of the overexpression of the
CD44 30-UTR and not due to the CD44 protein
upregulation resulting in downstream-signaling
pathways. Increased expression of CD44 and CDC42
was further conﬁrmed by immunostaining the tumor
sections and western blot analysis of tumor tissue
lysates. An elevated expression of CD44 and CDC42
proteins in the 30-UTR tumor was observed in both
immunostaining (Figure 5c) and western blotting (Figure
5d). The mRNA levels of CDC42 were analyzed in the
CD44 30-UTR and control cells by RT-PCR. The equal
levels of mRNAs suggest that the increased levels of
control
CD44 3’UTR
Cell Death CD34 Merge
Ctrl
Pair 1 Pair 2 center
CD44
UTR
(a)
(c)
(b)
high magnification low magnification
CD44
UTR
Ctrl
Figure 3. CD44 30-UTR expression promotes endothelial-cell activities and angiogenesis. (a) YPEN-1 cells were mixed with CD44 30-UTR and
control cells and inoculated in Matrigel
TM. Tube formation was examined with light microscopy. CD44 30-UTR mixed with YPEN-1 cells formed
larger complexes and longer tubes compared with the control cells mixed with YPEN-1 cells. Low magniﬁcation scale bars=400mm,
high-magniﬁcation scale bars=100mm. (b) Pairs of CD44 30-UTR and control tumor sections were stained with anti-CD34 antibody. There was
an increased number of blood vessels (arrows) in the CD44 30-UTR tumor sections compared with the controls. Scale bars=50mm. (c) The tumor
sections were co-immunostained with TUNEL for apoptotic cells (green) and CD34 to detect blood vessels (red). The CD44 30-UTR tumor sections
had an increased amount of apoptotic cell death and blood vessels compared with the control.
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Figure 4. Targeting of CDC42 by miR-216a, miR-330 and miR-608. (a) Computational analysis of the CD44 30-UTR has shown that miR-216a,
miR-330 and miR-608 could interact with both CD44 and CDC42 30-UTRs. Predicted binding sequences of miR-216a, miR-330 and miR-608 to
CD44 (upper) and targeting of CDC42 30-UTR by these miRNAs (lower) are shown. Mutated sequences in the seed regions of CDC42 are in red. (b)
We hypothesized that the overexpression of the CD44 30-UTR would attract endogenous miR-216a, miR-330 and miR-608, thus freeing CD44 and
CDC42 mRNAs to be available for translation. (c) The CDC42 30-UTR fragments were cloned into the luciferase reporter vector pMir-Report.
MT-1 cells were co-transfected with different miRNAs and the luciferase reporter construct harboring the CDC42 30-UTR or mutant CDC42
Continued
Nucleic Acids Research,2011, Vol.39, No. 8 3033CDC42 protein was regulated at the translation level
rather than the transcription level (Supplementary
Figure S3c).
As MT-1 is a human breast carcinoma cell line, we
sought to examine CD44 levels in human breast cancer
samples. Tumor sections from random patients were
immunostained with an anti-CD44 antibody. The levels
of CD44 were attenuated in the cells with a cancer pheno-
type, large and multiple nuclei, correspondingly with an
increase in CD44 protein levels in adjacent normal tissues
(Figure 6). It suggests that CD44 may function as a tumor
suppressor. Since the sections were randomly chosen, the
consistent results suggest that the association of tumor
progression with decreased expression of CD44 might be
important in clinical studies.
Corroboration of miRNA function
The function of miR-216a, miR-330 and miR-608 were
conﬁrmed by transfecting these miRNAs into stable
CD44 30-UTR and control MT-1 cells, followed by a
series of cell-functional assays. Proliferation rates were
monitored in miRNA transfected CD44 and control cells
over a period of 5 days. It was found that miR-330
increased the proliferation of control and CD44 MT-1
cells signiﬁcantly compared with the non-coding control
and miR-216a and miR-608 (Figure 7a and
Supplementary Figure S4a). This was further conﬁrmed
with cell cycle analysis in which miR-330 transfection
also resulted in a larger population of cells in the S and
G2 phases and decreased G1 phase population compared
with miR-216a, miR-608 and the non-coding control
(Figure 7b and Supplementary Figure S4b). These
results suggest that miR-330 is involved in cell prolifer-
ation and has the function to increase the proliferation
rate of MT-1 cells; thus, increasing the tumorigenic
properties of the cell line, while miR-216a and miR-608
decrease the tumor forming potential. In addition, cell
survival of miR-216a-, miR-330- and miR-608-transfected
CD44 30-UTR cells in low-serum conditions was
examined. There was an increased amount of cells that
survived when the CD44 30-UTR MT-1 cells were trans-
fected with the miRNAs compared with the control
sequence (Figure 7c). Endothelial tube formation was
analyzed in CD44 30-UTR MT-1 cells transfected with
the miRNAs which were mixed with YPEN-1 cells and
it was found that miR-216a and miR-608 inhibited the
formation of tubule structures while miR-330 allowed
the tubule like structures to form similar to the CD44
30-UTR. This experiment indicated that miR-608 and
miR-216a were involved in tubule formation (Figure 7d).
Furthermore, it was conﬁrmed that miR-216a, miR-330
and miR-608 were able to down regulate CDC42 protein
levels in the control MT-1 cells (Figure 7e). The
over-expression of the miRNAs allowed for the direct con-
ﬁrmation of the CD44 30-UTR function in MT-1 cells.
Conﬁrmation of CD44 30-UTR targeting
Small interfering RNA (siRNA) sequences were designed
to bind to the CD44 30-UTR region (Supplementary
Figure S4c). An unrelated sequence was used as a
control. The CD44 siRNAs were used to silence CD44
30-UTR expression to conﬁrm the functionality of the
CD44 30-UTR. The effectiveness of the siRNA treatments
were tested by RT–PCR for CD44 mRNA from the CD44
30-UTR cells transfected with the different siRNAs. The
treatments decreased the levels of CD44 mRNA
(Figure 8a). Western blot analysis was performed and
the siRNA-treated cells were found to have decreased
CD44 and CDC42 protein levels (Figure 8b). Cell-cycle
distribution was analyzed using FACs analysis. We
detected an increase in S and G2 phases in CD44
30-UTR siRNA-treated cells compared with control cells
which had a higher level of G1 phase population
(Figure 8c). We also detected lower levels of apoptosis
in the cells treated with siRNA-187, siRNA-199,
siRNA-541 and siRNA-650 (Figure 8d). This observation
concurred with the increase in cell proliferation and
survival of siRNA treatment (Supplementary Figures
S4d and S4e).
DISCUSSION
This study was designed to test our hypothesis that over-
expression of CD44 30-UTR in human breast-carcinoma
cells would function as a decoy when interacting with en-
dogenous miRNAs, thereby, arresting their function in
mRNA targeting. The mRNAs would be relieved of in-
hibition resulting in enhanced protein synthesis, and a
change in cellular activity or phenotype would be
expected. Our experiments provided strong evidence that
the overexpression of the CD44 30-UTR did indeed affect
the activities of the breast-carcinoma cells MT-1 in terms
of cell proliferation, cell cycle progression, survival, apop-
tosis, formation of tube-like structures in vitro and blood
vessel formation and tumor growth in vivo.
Initially, we observed the overexpression of the CD44
30-UTR inhibited the proliferation rate of MT-1 cells. We
speculated that the exogenous CD44 30-UTR mechanistic-
ally decreased the proliferation of MT-1 cells by binding
Figure 4. Continued
fragment in MT-1 cells. A non-related fragment of cDNA was used as a control. Luciferase activity assays indicated that all three miRNAs repressed
luciferase activities when it harbored the corresponding CDC42 30-UTR, which were reversed when the potential miRNA target site was mutated.
n=3,*P<0.05. (d) The luciferase reporter plasmids were co-transfected with corresponding miRNAs or control sequence and the pcDNA3.1–CD44
30-UTR or pcDNA3.1-G3R into MT-1 cells. The inhibitory effects of miRNAs could be signiﬁcantly recovered in the presence of pcDNA3.1-CD44
30-UTR. n=3, *P<0.05, **P<0.01. (e) The luciferase reporter vector harboring the CD44 30-UTR (Luc-CD44 30-UTR) or a control was trans-
fected at different concentrations in MT-1 cells. Luciferase activities were normalized using the control as 100%. The luciferase activities of
Luc-CD44 30-UTR never reached the control values. However, the luciferase activities increased with higher doses of plasmids. An increase in
CD44 30-UTR concentrations results in increasing luciferase activities. n=3. (f) The Luc-CD44 30-UTR or control was co-transfected with the
pcDNA3.1-CD44 30-UTR construct at different amounts in MT-1 cells. With an increase of pcDNA3.1-CD44 30-UTR, more endogenous miRNAs
were bound, freeing the translation of luciferase protein and resulting in higher levels of luciferase activities. n=3.
3034 Nucleic Acids Research, 2011,Vol.39, No. 8to endogenous miRNAs and inhibiting downstream pro-
liferative activities. Data supporting this observation was
obtained from cell-cycle progression assays. We found
that cells overexpressing CD44 30-UTR displayed signiﬁ-
cantly higher levels of G1 population than the cells trans-
fected with an empty vector. Since these experiments were
performed in a human breast-carcinoma cell line MT-1,
we tested how these effects could be translated to an
in vivo phenotype. Our ﬁndings from the tumor formation
experiments were consistent with that of cell proliferation
and cell cycle progression. It should be noted that cell
proliferation only represents one aspect of tumorigenicity,
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membranes served as a loading control. Increased expression of CD44 and CDC42 was detected in the CD44 30-UTR-transfected cells. (b) Protein
lysates were prepared from CD44 30-UTR- and CD44E-transfected cells and subjected to western-blot analysis probed with anti-CD44 and -CDC42
antibodies. Although transfection with CD44E increased CD44 expression, it did not increase CDC42 level. (c) Immunohistochemistry was per-
formed on tumor sections with anti-CD44 and -CDC42 antibodies. There was an increase in CD44 and CDC42 in the CD44 30-UTR tumor sections
compared to the control sections. Scale bars=100mm. (d) Protein lysates were prepared from CD44 30-UTR and control tumors and subjected to
western-blot analysis probed with anti-CD44 and -CDC42 antibodies. b-actin detection on the same membranes served as a loading control. Both
CD44 and CDC42 were up-regulated in the CD44 30-UTR tumors.
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3036 Nucleic Acids Research, 2011,Vol.39, No. 8and increased cell proliferation cannot always be
translated to enhanced tumorigenesis. On the other
hand, cell survival, especially in poor conditions such as
in serum-free medium, is always correlated with tumori-
genicity (32). Thus, a decreased cell survival in vitro can
normally be translated to decreased tumorigenesis.
Cell death is another important aspect of tumor growth.
In non-optimal conditions and in the presence of
chemotherapeutics, we detected an increased sensitivity
of CD44 30-UTR cells to nutrition depletion as
compared with the control cells. Furthermore, this pheno-
type was also observed in our in vivo studies. The presence
of nuclear condensation and fragmentation and increased
TUNEL staining observed in the tumors formed by the
CD44 30-UTR -transfected cells demonstrated the occur-
rence of extensive cell death. This could explain why CD44
30-UTR tumors displayed a slower growth rate than the
control tumors. The increase in cell survival with the
overexpression of miRNAs in CD44 30-UTR -transfected
cells revealed that the cell death could be a result of the
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Figure 7. Functions of miR-216a, miR-330 and miR-608 in MT-1 cell line. (a) The proliferation rate was measured in the CD44 30-UTR cells
transfected with miR-216a, miR-330 and miR-608 over a period of 5 days. Expression of miR-330 increased proliferation of CD44 30-UTR cells.
n=5, **P<0.01. (b) Cell-cycle progression of the miRNA transfected CD44 30-UTR cells were analyzed by FACs analysis. Transfection with
miR-330 decreased G1 population but increased G2 and S populations in the CD44 30-UTR cells. n=3.(c) Cell survival was examined in the CD44
30-UTR MT-1 cells transfected with miR-216a, miR-330 and miR-608. Expression of miR-216a, miR-330 and miR-608 increased cell viability. n=5,
**P<0.01. (d) Tube formation was analyzed in the CD44 30-UTR cells transfected with miR-216a, miR-330 and miR-608. Expression of miR-216a
and miR-608 inhibited the formation of tubule structures in the CD44 30-UTR MT-1 cell line. Scale bars=250mm. (e) Cell lysates of miRNAs
transfected into MT-1 cells were analyzed by western blot. Expression of these three miRNAs repressed CDC42 levels.
Nucleic Acids Research,2011, Vol.39, No. 8 3037increasing amount of apoptotic proteins due to CD44
30-UTR expression, since increased CD44 30-UTR levels
could bind and arrest endogenous miRNA functions in
MT-1 cells. These downstream apoptotic effects require
further investigation in order to determine the identity
of the proteins involved.
To understand the mechanism of how the CD44
30-UTR works in a cellular context, we analyzed potential
miRNAs that could bind to CD44 30-UTR with low
energy and found that there are many miRNAs that can
possibly do so. Since each miRNA can potentially target a
great number of mRNAs with sites that perfectly match
their seed regions, it is impossible to analyze all mRNAs
with sites that match the seed regions of these potential
CD44 30-UTR-interacting miRNAs. Rather, we focused
on genes that play an important role in cell proliferation,
cell cycle progression, cell survival and apoptosis.
Interestingly, we found that miR-216a, miR-330 and
miR-608 can potentially target both the CD44 and
CDC42 30-UTRs.
CD44 is a cell surface receptor for hyaluronan binding
and plays an important role in mediating cell adhesion
(4,40). Increased expression of CD44 is expected to
modulate the activities of nearby cells including endothe-
lial cells, affecting angiogenesis. We have previously
demonstrated that expression of a microRNA (miR-328)
controlled the morphogenesis of cells and tissues by tar-
geting CD44 expression (9). Decreased CD44 expression
would reduce hyaluronan-binding capacity and cell–cell
and cell–matrix interactions. This is in consistent with
our current report that increased expression of
CD44-promoted angiogenesis. Recently, we also found
(a)
(b)
(c)
(d)
Figure 8. siRNA against the CD44 30-UTR enhances proliferation and decreases CD44 and CDC42 protein levels and apoptosis. (a) Total RNA was
collected from CD44 30-UTR cells transfected with different siRNAs targeting CD44 30-UTR. These samples were used in RT–PCR to measure
CD44 mRNA levels. All siRNAs were found to decrease the levels of CD44 mRNA. (b) CD44 30-UTR and control cells were transfected with
different siRNAs targeting the CD44 30-UTR. Cell lysates were subjected to western-blot analysis. Both CD44 and CDC42 levels decreased as a
result of siRNA targeting CD44 30-UTR. (c) Cell-cycle distribution was analyzed. There was an increase in the S and G2 phases of the siRNA treated
cells compared with the control, which had an increased G1 population. n=3.(d) Apoptosis of the siRNA treatment was analyzed using Annexin V
staining. Treatments with siRNA-187, siRNA-541 and siRNA-650 decreased apoptosis compared with the control. n=5.
3038 Nucleic Acids Research, 2011,Vol.39, No. 8that the expression of miR-93 repressed expression of
integrin b8, a cell-surface receptor modulating cell
adhesion and proliferation. As a consequence,
endothelial-cell activities and angiogenesis were affected
(41), suggesting that cell surface receptors play important
roles in mediating endothelial-cell activities.
It is conceivable that the overexpression of the CD44
30-UTR would enhance CD44 expression, since the
expressed CD44 30-UTR binds identical miRNAs as
compared with the endogenous CD44 mRNA. This is sup-
ported by our recent study showing that expression
of versican 30-UTR promoted versican expression (29).
The effect of the CD44 30-UTR on the expression of
other genes is more complicated, since there may be
many miRNAs that can bind to both 30-UTRs with a
high afﬁnity. Computational analysis indicated that
miR-216a, miR-330 and miR-608 potentially targeted
both CD44 and CDC42 30-UTRs. We thus focused on
CDC42, as we expected that, with more miRNAs (three
in our study) potentially targeting CDC42 and binding to
CD44 30-UTR, the decoy effect of CD44 30-UTR would
be more evident. Indeed, our data demonstrated that
overexpression of the CD44 30-UTR not only up-regulated
CD44 expression but also increased CDC42 protein levels.
The CD44 30-UTR functioned as a decoy sponge binding
to miR-216a, miR-330 and miR-608, resulting in increased
CD44 and CDC42 protein levels. This conclusion was sup-
ported by the detection of equal levels of CDC42 mRNAs
in both the control and CD44 30-UTR-transfected cells,
suggesting that the increased levels of CDC42 protein were
due to regulation at the translational level. An additional
result to support this ﬁnding was obtained by exogenously
expressing a CD44E construct, showing that the increased
expression of CDC42 was not due to CD44 protein
upregulation. Rather, it was due to the overexpression
of CD44 30-UTR, which arrested the functions of
relevant miRNAs.
The tube-formation assays performed with Matrigel
TM
appeared to be an ideal approach to test the effect of CD44
30-UTR on angiogenesis, since the results obtained by
this method and the results obtained by studying angio-
genesis in tumors were consistent. While angiogenesis
in an in vivo setting is the consequence of the activity
of many genes, studying angiogenesis via tube-
formation assay performed in Matrigel
TM is relatively
simple. From this study, it appears that CD44, a major
cell-surface glycoprotein involved in cell–cell and cell–
matrix interactions, mediated the effects that the tumor
cells hadon the endothelial cells. This result is in agreement
withourprevious reportthatCD44plays aroleinzonation
morphogenesis and in the formation of tube-like struc-
tures (9). The ability of the CD44 30-UTR cells to
modulate tubule-like-structure formation when mixed
with YPEN-1 cells and the corresponding data displaying
increased formation of blood vessels in CD44 30-UTR
tumors demonstrated the potential of CD44 30-UTR in
angiogenic and anti-angiogenic therapies.
During our analysis of tumor angiogenesis, we unex-
pectedly observed more CD34 staining and larger blood
vessels in the CD44 30-UTR tumor sections than in the
control group, although these tumors were smaller than
those formed by the control cells. Usually, larger tumors
would require more blood vessels to provide nutrients,
allowing the tumor cells to survive and grow. As such,
angiogenesis is an important criterion of tumorigenesis.
In this aspect, we were also surprised to detect extensive
cell death surrounding the blood vessels. These results
indicate that the increased amount of blood vessel forma-
tion was unable to rescue the CD44 30-UTR cells from
death. Our results suggest that there are different sets of
genes in regulating angiogenesis and tumorigenesis. CD44
30-UTR may be adopted in future studies to dissect genes
that regulate angiogenesis and/or tumorigenesis.
When we found that miR-216a, miR-330 and miR-608
can all interact with CD44 30-UTR as well as target
CDC42 30-UTR, we tested the possibility that all of
these miRNAs may function together in mediating
CD44 30-UTR effects. This idea is related to the concept
that microRNAs with similar functions cluster together in
various disease processes (41). However, in our function
dissecting experiments, we found that increased levels of
miR-330 promoted cell proliferation, suggesting that the
arrest of miR-330 function inhibits cell proliferation, a
result observed when CD44 30-UTR was expressed. On
the other hand, up-regulation of miR-216a and miR-608
inhibited formation of tube-like structures, suggesting that
arrest of miR-216a and miR-608 (by the overexpression of
CD44 30-UTR) would increase formation of tube-like
structures, a result observed when CD44 30-UTR express-
ing cells were employed. This could explain why we
observed enhanced angiogenesis and inhibited tumor
growth when the CD44 30-UTR was overexpressed. It
appears that the effects of a 30-UTR are very complex as
compared with the effects induced by a gene or a miRNA.
Considering the number of miRNAs that can interact with
a3 0-UTR, we conclude that 30-UTR can not only function
as a mediator of miRNA-regulating gene expression, but
also as a modulator-regulating miRNA functions. In the
latter case, the great number of 30-UTRs in a cell may also
function as a buffer system to modulate and to ﬁne-tune
miRNA activity.
In summary, we have found that CD44 30-UTR inhibits
proliferation, colony formation, and tumor formation. It
also induces apoptosis, promotes endothelial-cell
activities, favors angiogenesis and shows an increased sen-
sitivity to chemotherapeutics as a result of endogenous
miRNAs binding to the exogenously introduced CD44
30-UTR. Furthermore, it was found that miR-330 is im-
perative in regulating cell proliferation and MT-1 endo-
thelial cell activities. Due to the interaction of the CD44
30-UTR and CDC42 30-UTR with miR-216a, miR-330
and miR-608, expression of exogenous CD44 30-UTR
increased CD44 and CDC42 protein levels. This
overexpression of a non-coding transcript freed the poten-
tial targets of the miRNAs and led to an up-regulation of
multiple protein levels. The 30-UTR can thus be used as a
functional miRNA inhibitor that is capable of modulating
multiple miRNAs rather than just one. In this capacity,
the 30-UTR can be used to bind to multiple oncogenic
miRNAs, which is a characteristic that can be exploited
and potentially applied to gene therapy.
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